EPHA5

Ephrin type-A receptor 5 · P54756 · EPHA5 on Sugi Atlas →

10,388 patent compounds predicted against EPHA5, 8,769 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sorafenib (SCHEMBL8218)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL8226)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	2/20
Regorafenib (SCHEMBL432230)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL1363032)	0.94	2/20
Dasatinib Anhydrous (SCHEMBL1362204)	0.90	2/20
SCHEMBL620651	0.84	2/20
SCHEMBL1147156	0.84	2/20
SCHEMBL1147171	0.84	2/20
SCHEMBL1146489	0.81	2/20
Sorafenib (SCHEMBL162935)	0.81	2/20
SCHEMBL937568	0.81	2/20
SCHEMBL1146496	0.81	2/20
SCHEMBL432444	0.81	2/20
SCHEMBL170976	0.80	2/20
SCHEMBL1147074	0.80	2/20
Sorafenib (SCHEMBL19322)	0.80	2/20
SCHEMBL1147022	0.79	2/20
SCHEMBL1147135	0.79	2/20
SCHEMBL1147164	0.79	2/20

Clinical trials — most relevant to EPHA5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction	PHASE4	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma	PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer	PHASE2	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Isolation of Cells From Biopsy Tissue to Aid in Kidney Repair	PHASE1	WITHDRAWN
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Genetics of Arteriovenous Malformations	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)	nan	RECRUITING
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
Spinal Cord Stimulation for Spinal Cord Injury Patients - Regain Walk and Alleviate Pain	nan	RECRUITING
Epidural Electrical Stimulation for Spinal Cord Injury Patients and Corticospinal Motor Circuit Improvement	nan	RECRUITING
Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia	nan	COMPLETED
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers	nan	UNKNOWN
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
HYPGENE-Genetics Fitness Obesity & Risk of Hypertension	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHA5 binder may also engage these)

Protein	Name	Similarity
Q60629	—	1.000	Q60629 →
P54755	—	1.000	P54755 →
Q03145	—	1.000	Q03145 →
Q91735	—	1.000	Q91735 →
Q07497	—	1.000	Q07497 →
O42422	—	1.000	O42422 →
Q1KL86	—	1.000	Q1KL86 →
P54757	—	1.000	P54757 →
EPHA3	Ephrin type-A receptor 3	1.000	landscape →
Q90344	—	1.000	Q90344 →
Q62413	—	1.000	Q62413 →
P09759	—	1.000	P09759 →
EPHB3	Ephrin type-B receptor 3	1.000	landscape →
EPHA7	Ephrin type-A receptor 7	1.000	landscape →
Q61772	—	1.000	Q61772 →
Q91694	—	1.000	Q91694 →
O08680	—	1.000	O08680 →
O13146	—	1.000	O13146 →
Q03137	—	1.000	Q03137 →
Q91571	—	1.000	Q91571 →
O73875	—	0.999	O73875 →
P54758	—	0.999	P54758 →
P29318	—	0.999	P29318 →
P29319	—	0.999	P29319 →
EPHA2	Ephrin type-A receptor 2	0.999	landscape →
Q91845	—	0.998	Q91845 →
O09127	—	0.998	O09127 →
P54763	—	0.998	P54763 →
Q07496	—	0.998	Q07496 →
EPHB1	Ephrin type-B receptor 1	0.998	landscape →